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Non-Hodgkin’s lymphoma (NHL) is clinically a heterogeneous
group of malignancies for which the B-cell phenotype constitutes
85% of the cases. For the indolent non-localized lymphomas there
is no curative treatment, but median overall survival is close to 10
years and differs markedly between patients. Approximately 40%
of aggressive NHL are cured by combination chemotherapy
(Fisher et al, 1993). Lymphoma sub-types (Harris et al, 1994) and
prognostic factors like stage, age, serum LDH, WHO perfor-
mance, and number of extranodal sites (The International Non-
Hodgkin’s Lymphoma Prognostic Factors Project, 1993) are
presently the tools for treatment selection and the background for
informing the patient on life expectancy. 
The development of B-cell NHL is, as for other neoplasias,
accompanied by the sequential acquisition of monoclonal genetic
aberrations. Typical aberrations in B-cell NHL include transloca-
tions involving the immunoglobulin loci and other chromosomal
loci harbouring proto-oncogenes like c-MYC, BCL-1, BCL-2, and
BCL-6 (Rabbitts, 1994; Ong and Le Beau, 1998). These transloca-
tions activate inappropriate transcription of the proto-oncogene
involved, and may, together with loss of tumour suppressor activi-
ties, lead to deregulated growth due to increased proliferation or
decreased apoptosis. Losses and gains of tumour suppressor genes
and proto-oncogenes or larger genomic regions containing such
genes are common events in the genesis of most solid tumours.
Classical cytogenetic studies have revealed that unbalanced
translocations and gains and losses of whole chromosomes are
frequent also in NHL (Offit, 1992; Mitelman et al, 1997; Ong and
Le Beau, 1998). 
Comparative genomic hybridization (CGH) is based on
hybridization of tumour DNA from interphase cells to normal
metaphases for the detection of gain or loss of specific chromo-
somal regions. CGH does not provide any information about the
chromosomal organization of the tumour genome, but has several
advantages compared to classical cytogenetics: Interphase cells
can be analysed without the need for culturing to make metaphase
spreads; The composition of complex marker chromosomes,
which can be difficult to analyse by cytogenetics, is easily
obtained by CGH. In agreement with the classical cytogenetic
studies, CGH studies of B-cell NHL have shown genomic losses
and gains to be frequent in follicle centre lymphomas (FCL, Bentz
et al, 1996), small lymphocytic lymphomas/chronic lymphocytic
leukemias (SLL/CLL, Bentz et al, 1995), mantle cell lymphomas
(MCL, Monni et al, 1998; Beà et al, 1999; Bentz et al, 2000), and
diffuse large B cell lymphomas (DLBCL, Monni et al, 1996). 
Specific sub-types of NHL are characterized by specific chro-
mosomal translocations. However, it is less well known whether
additional chromosomal changes are also confined to certain
lymphoma sub-types, and whether these correlate with prognosis.
The results of numerous reports strongly suggest that the presence
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of aberrations in the p53 pathway (i.e. 17p deletions, TP53 muta-
tions, expression of wild-type p53) are adverse prognostic factors
in NHL (Sander et al, 1993; Tilly et al, 1994; Dohner et al, 1995;
Schoch et al, 1995; Hernandez et al, 1996; Panayiotidis and Kotsi,
1999; Dohner et al, 2000; Stokke et al, 2000; reviewed by
Knutsen, 1998). Chromosomal aberrations are important prog-
nostic factors and are used for treatment stratification in acute
lymphoblastic leukaemia, including the indication for bone
marrow transplantation in first remission (Pui and Evans, 1998). 
We report here the findings of a CGH study of 94 cases of
randomly selected B-cell NHL. The chromosomal gains and losses
were compared with lymphoma subtype, S phase and apoptotic
fraction, as well as prognosis. 
MATERIALS AND METHODS 
Patients 
The 94 patients included in this study were randomly selected
based on the diagnosis of B-cell non-Hodgkin’s lymphoma and on
the availability of frozen cell suspensions (in DMSO) with more
than 50% tumour cells (Ig-expressing cells by manual counting
and flow cytometry). All patients were hospitalized at our institu-
tion during the period 1983–1993. Lymphoma subtyping was
performed according to the REAL classification (Harris et al,
1994). Twelve of the 13 MCL cases in this study had cyclin D1
expression and t(11;14) (lacking in case 67/92), and 32 of the 36
FCL cases had t(14;18) (lacking in cases 577/90, 489/91, 533/91,
and 300/92). 
Clinical data were available for 92 of the patients (lacking in
cases 159/90 and 244/91). The age range of these patients at the
time of the relevant biopsy was 31–86 years, the median age was
57 years, and 41 of the patients were women (42 of the total of 94).
For 62 patients, the biopsy was taken at diagnosis, for 15 patients
at first relapse, and for 15 patients at second or later
relapse/progression. No patients had received chemotherapy
during the last month before the biopsies. The median follow-up of
the 31 survivors was 59 months. Clinical stage was according to
the Ann Arbor classification (Carbone et al, 1971) at the time of
diagnosis. The patients were clinically examined and received
standard blood testing, standard X-ray of the thorax, CT scan of
the abdomen/pelvis and, if necessary, of the thorax, as well as
bilateral bone marrow aspiration/biopsy. 
Patients with DLBCL and BL were treated according to the
following protocols: Eight courses of CHOP (cyclophosphamide
750 mg/m2 i.v. day 1, doxorubicin 50 mg/m2 i.v. day 1, vincristin
2 mg day 1, and prednisone 100 mg p.o. day 1–5) for stage III–IV,
and 6 courses of CHOP followed by involved field radiotherapy
for patients with stage I disease. If two neighbouring lymph node
regions were involved, stage II DLBCL and BL patients were
treated as stage I patients, otherwise, treatment was as for stage
III–IV. For the SLL, MZL, FCL, and MCL lymphomas, the
following treatment was given: When required, initial therapy to
the patients consisted of radiotherapy to stage I–II disease, while
patients with stage III–IV disease were given the CVP regimen
(cyclophosphamide 750 mg/m2 i.v. day 1, vincristin 2 mg day 1,
and prednisone 100 mg p.o. day 1–5) during the early part of the
study period, whereas chlorambucil 6 mg/m2 p.o. and prednisone
5–10 mg p.o. daily for up to 6 months was given during the latter
part of the period. Younger patients with an aggressive clinical
course were given CHOP at the discretion of the responsible 
clinician. The CVP and CHOP regimens were repeated every 3
weeks for a total of 6–8 courses; the chemotherapy regimen was
changed if at least a partial remission was not achieved within 2–3
months of therapy. Treatment at relapse or progression was given
at the discretion of the responsible clinician. No patients had
received chemotherapy during the last month before the biopsies
were taken. 
Comparative genomic hybridization 
The isolation of genomic DNA from the (thawed) lymphoma
samples was performed after a standard protocol based upon
proteinase K and dodecyl sulphate as described by DeAngelis et al
(1999). The DNA concentration was determined by Hoechst
33258 staining and measuring the fluorescence in a fluorimeter. 
Genomic DNA was nick-translated and labelled with either
Texas red-5-dUTP for normal sex-matched DNA or FITC-12-
dUTP for tumor DNA (Kallioniemi et al, 1994a; DeAngelis et al,
1999). 
The slides for CGH hybridization were prepared following
routine procedures for PHA stimulated, methotrexate synchro-
nized, peripheral blood lymphocytes. After dripping the cells onto
the slides at 60–65% relative humidity, the slides were stored at
–20˚C in 100% ethanol or at 0˚C in a nitrogen flushed container. 
Denaturation, hybridization, and counterstaining with DAPI
was essentially performed as outlined by Kallioniemi et al
(1994a), and in more detail as described by DeAngelis et al
(1999). 
Microscopy and data treatment 
DAPI fluorescence and probe signals were observed sequentially
with a Zeiss Axioplan fluorescence microscope equipped with a
triple-pass emission filter (blue, green and red), a corresponding
beam splitter, and separate excitation filters (UV, 470–490 nm,
578 nm). All filters (‘Pinkel 1’ filter set) were obtained from
Chroma, Brattleboro, VT. Images were captured and digitized in a
cooled 16 bit CCD camera (Astromed, Cambridge, UK). 
Segmentation and calculation of ratio profiles were performed
with software that was kindly provided by D. Sudar. The software
ran under the ‘Scilimage’ image analysis program (TNO, Delft,
Netherlands). Hybridizations were repeated when the FITC or the
Texas Red chromosomal fluorescence was low (signal to back-
ground less than ~ 2), or grainy, or when blocking of (labelled)
probe hybridization to centromere regions and the p-arms of acro-
centrics was not satisfactory. Each tumour was satisfactory. Each
tumour was hybridized 2.6 times on the average to get acceptable
results. The average and standard deviation of several (>3) profiles
of each chromosome were calculated, and more profiles were
added until the averaged profile and standard deviation did not
change after the addition of a new one. When using these criteria,
ratios less than 0.85 and larger than 1.15 were never observed in
normal versus normal hybridizations. Gains and losses were there-
fore scored if the ratio was above 1.15 and below 0.85, respec-
tively (DeAngelis et al, 1999). 
DNA flow cytometry 
The flow cytometry procedure for determination of tumor-
specific S-phase fraction and apoptosis has been described
(Stokke et al, 1998a). Briefly, thawed cells were labelled with1902 T Stokke et al
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phycoerythrin-labelled light chain antibodies for the tumour-
characteristic light chain and washed. The cells were thereafter fixed
with 1% paraformaldehyde followed by 100% methanol and
labelled with FITC-dUTP after incorporation by terminal deoxynu-
cleotidyl transferase for the detection of apoptotic cells, and Hoechst
33258 for assessment of DNA content. After gating away aggre-
gates of cells and apoptotic cells, DNA histograms of the tumour
cells and normal cells were obtained by gating on the light chain
positive and negative cells, respectively. The fraction of tumour cells
was assumed to be equal to the fraction of cells expressing the
tumour-characteristic light chain. Ploidy, i.e. DNA index (DI), was
calculated as the ratio between the G1 peak positions of the tumour
cells and the normal cells. 
Statistical analysis 
Relevant statistical tests were performed using the ‘SigmaStat’
(Jandel Scientific, Erkrath, Germany) and ‘SPSS’ (SPSS, Chicago,
IL) software packages. Relative risks were calculated using Cox
uni-and multi-variate regression analysis. Relative risk (RR) is the
time-averaged ratio between the fractional survivals in the two
groups defined by the assessed variable. P-values were calculated
using Cox regression analysis and the log-rank test. P-values
below 0.05 were considered to reflect statistical significance.
Cancer-specific survival was determined from the time of the rele-
vant biopsy. Death from any cancer or treatment complications
defined an event. Other deaths were censored. The Kaplan-Meier
method was used to generate survival curves. 
RESULTS 
CGH aberrations in NHL 
Ninety-four cases of B-cell NHL were analysed for chromosomal
aberrations by CGH. Table 1 and Figure 1 contain the complete
results obtained by CGH, as well as the DNA index for all 94
lymphomas. Regions with a ratio above 1.5 are written in bold print
in Table 1 and displayed in bold print in Figure 1. As an example,
Figure 2 shows the results obtained for seven of the tumours with
respect to chromosomes 1, 3, 9, and 18. Large-scale aberrations, i.e.
aberrations detectable by CGH, were found in 80 of 94 tumours
(85%), including a majority of the tumours that were found to be
DNA diploid by flow cytometry (Table 1). The mean fraction of
tumour cells was not different in the samples with and without CGH
aberrations (75% for both groups; P = 0.88), indicating that the lack
of observed aberrations cannot be attributed to a low fraction of
tumour cells. The CGH aberrations were non-random, and some of
them were local. For classification of an aberration as local, i.e. not
encompassing the whole chromosome, we required that at least
three tumours defined any border around the ‘consensus region’.
The two arms of a chromosome were not assumed to be separate
entities, and aberrations outside the consensus region(s) on a given
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Figure 1 Chromosome ideogram with losses (left) and gains (right) in 94 cases of NHL. Bold lines represent regions where the green/red fluorescence ratio
exceeded 1.5 (`high-level’ amplifications). G
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Table 1 Chromosomal aberrations in 94 cases of B-cell NHL 
Case Lymphoma  Sex CGH losses CGH gainsb DNA No. c-MYC No.  RB1 No. TP53
subtype  indexc allelesd allelesd allelesd
(REAL)a
Small lymphocytic lymphoma
140/83 SLL M None None 1.00 2 1 2 
086/85 SLL M 11q14–23.1 None 1.00 2 2 
320/88 SLL F X None 1.00 2 2 2 
325/88 SLL* M None None 1.00 
416/88 SLL M 17p 12 1.03 2 2 1 
470/88 SLL M None 10cen-q21.1, 12qcen-13, 12q22-ter 1.02 
191/89 SLL M None 12 1.02 2 2 2 
339/89 SLL* F 8p21-ter, 11q14–23.1, 13q12.3-ter 3q, 3q21-ter, 5p, 7p13-ter, 8q22-ter, 17q21.3-ter 1.00  3 1 2 
445/89 SLL M None 2p14–16, 3  1.02 2 
452/89 SLL M 14q24-ter None 1.00 2 
051/90 SLL M 1q41-ter, 17p 1cen-q31, 3q, 18q12.3-ter, 22q13-ter 1.05 2 2 1 
159/90 SLL F None 12 1.04 
571/90 SLL M 11q22–23.1 None 1.00 
156/91 SLL* F 11q21–23, 15q14–21 None 1.00 2 2 2 
244/91 SLL M None None 1.00 2 2 2 
462/91 SLL* F 17p 11q23-ter, 12pter-q15, 13q31-ter, 20p 1.00 2 2 1 
225/92 SLL M None 12 1.03 
315/92 SLL M None 12, 15q25-ter 1.00  2 1 2 
538/92 SLL M 8cen-p21 3q21-ter, 8q23-ter  1.00 
Marginal zone lymphoma
315/88 MZL M None 12 1.00 2 1 2 
237/91 MZL* M 11q14.3–23 None 1.00 
448/91 MZL M None 3, 18, 19 1.05  2 2 
Follicle centre lymphoma
377/83 FCL I/II M None 7pter-q12  1.00 2 2 2 
364/86 FCL I/II + SLL F 19p13.2-ter  18pter-q21 1.02 
369/86 FCL I* F None None 1.02 
021/87 FCL I/II M None 18pter-q21.1  1.00 
241/87 FCL I/II F None None 1.02  2 2 
345/87 FCL II F None 18q 1.00 
018/88 FCL II F None 1p21–22, 13q21-ter 1.00 2 2 2 
041/88 FCL II F None 18q12.3-ter  1.03 
046/88 FCL II* F None None 0.97  2 2 2 
047/88 FCL I/II* M 6cen-q22, 13q13–21.1 None 1.00 2 1 2 
176/88 FCL II F None 7, 8q21.3-ter, 18q12–22 1.04 
233/88 FCL II F 6q14-ter, 13cen-q22 None  1.00 2 1 2 
275/88 FCL I/II M None None 1.00  2 2 2 
284/88 FCL II F None 20pter-q12, 22cen-q12 1.02 2 2 2 
381/88 FCL II M None 18, X 1.03 
399/88 FCL III M 6cen-q24, 17p 1p34.3-ter, 8q24-ter, 17q, 22q 1.00 2 2 1 
468/88 FCL I M None 15q25-ter 1.00 
064/89 FCL II* F 1cen-p22.2 1q32-ter, 6pter-q15, 12pter-q21, 12q14, 13q31-ter,  1.26 2  2 3 
13q32-ter, 16, 20q, 20q13, 21q22
287/89 FCL I M 6q14–22.1 2 1.03 1
9
0
4
T
 
S
t
o
k
k
e
 
e
t
 
a
l
B
r
i
t
i
s
h
 
J
o
u
r
n
a
l
 
o
f
 
C
a
n
c
e
r
 
(
2
0
0
1
)
 
8
5
(
1
2
)
,
 
1
9
0
0
–
1
9
1
3
©
2
0
0
1
 
C
a
n
c
e
r
 
R
e
s
e
a
r
c
h
 
C
a
m
p
a
i
g
n
(Table 1 Continued)
311/89 FCL II F None  7q21–31, 13q32-ter, X 1.05 2 2 2 
521/89 FCL II F None 17q24-ter, 20, 21q  1.00 
140/90 FCL II* M None 1q41-ter, 17, 18  1.03 
372/90 FCL II* F 17p 1q41-ter, 7p13-ter  1.07 
377/90 FCL II F None 2cen-q22, 2q36-ter  1.06 2 2 
416/90 FCL II M None None 1.00 2 2 
577/90 FCL II M 5, 9p, 17p 3, 12, X  1.97 
581/90 FCL II* F 17p  1q,3,5,7,10,12q,17q,18q12.3–21,X 1.22 
635/90 FCL I/II* M None None 1.00 
382/91 FCL II* M 16cen-q13 17q 1.02  2 2 2 
436/91 FCL II M None 18, 18pter-q21 1.04 
489/91 FCL I/II* M None  12q13–15,17q21–22 1.03 
533/91 FCL II F None None 1.00 
021/92 FCL II F 16cen-q13,X 12q24.2-ter,17q 1.02 
103/92 FCL II* M 1p35-ter 1q 1.00  2 2 
130/92 FCL I/II* M None 12cen-q13,16p,18,19 1.03 
300/92 FCL II M 17p 3q24-ter 1.00  2 2 
Mantle cell lymphoma
123/84 MCL* M 9p21-ter,11q23-ter,13q21.3-ter, 3q22-ter,10cen-p13, 10p12,Xq27-ter 1.04 2 
22q12.2-ter
358/87 MCL* F 2q,6q,8p21-ter,9pter-q33, 11p12-ter, 3,6p,7,8q21.2-ter,15q21-ter  1.94 3 
13q,14q21-ter
154/88 MCL M 1p21–31,5p14-q13.1,8p,9,12q 1p34-ter,16,16p13.3,19,22cen-12.1 0.95 2 1 2 
15-ter,13q 
265/88 MCL* F 1p,9p21-ter,11p12-ter, 18p 11q13-ter,18q12-ter 1.00 2  2 2 
010/89 MCL* M 1p21–31.1,9p21-ter,11q21–23.1, 3q21-ter 1.00 1 2 
13cen-21.1,18p 
129/89 MCL* F 3cen-p14,8p,11q14–23 3q21-ter,4q33-ter,5p,8q22-ter  1.02 3 2 2 
309/89 MCL* M 1p13.3–31,6q,9p21-ter,13q, 6p 1.83 3+4 2+3 3 
14q21–24.1,22q12.2-ter
472/90 MCL F None 2p13-ter,5,6p22-ter,7p,7p,8q23-ter,8q23-ter,10p12-ter, 1.16 2 2
12,17q24-ter,18pter-q21
383/91 MCL M 9pter-q22,13q 9q34-ter 0.97 1 
428/91 MCL M 1p31.1-q25 None 2.00 4 4 4 
037/92 MCL* F 7q31–32,9p,17p 17q24-ter,21q21-ter 1.00 2 2 1 
067/92 MCL* M 1p21,8p,9pter-q31,11q22–23.1, 3q21–23,3q26-ter,8q,15q21.2-ter, 15q24-ter 0.98 3 1 2 
13q,22q12-ter
245/92 MCL* M None 3q, 3q21-ter 1.03 2 2 
Diffuse large B-cell lymphoma
122/84 DLBCL F 1p21–31.1,2p23-ter,2q23-ter, 7,7p13,7q22,11q23.3-ter,16p 1.23 2 2 1
2q23–33,5q,6q,8pter-q21,15cen-q21,17p 
255/85 DLBCL F 6q,10pter-q11,12p 3,6p,7p,7p,18q21-ter 1.04 2 2 
377/87 DLBCL* M 13q13–14 None 1.03 1 2 
390/87 DLBCL M 18q 1q,11q14-ter,11q22.2-ter 1.00 2 2 2 
399/87 DLBCL F X 1p31.2-ter,5q,12, 15q23-ter,17q21.3-ter,19q 1.06 2 2 2 
258/88 DLBCL* M 5,17p 6p,8q23-ter,12q21.3-ter,13q31-ter,21,Xp 1.07 3+4 2+4 1+2 
287/88 DLBCL* F 4,17p,18p 8cen-p12,12,15q21-ter,18cen-q22,Xp 1.00 
454/88 DLBCL F 6q,11q13-ter,17p 10,17q,22q 1.02 2 1 
131/89 DLBCL M 1p21–32,8p12-q12 3q,7pter-q11,8q23-ter,9q22-ter,16p,18 2.23 8  4 4 
438/89 DLBCL F 2q24–34,14q24.3-ter None 1.00 2 2 2 Genomic imbalances and prognosis in non-Hodgkin’s lymphoma 1905
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chromosome were assumed to have arisen as a consequence of the
gain or loss of important gene(s) within the consensus region. The
most frequent (≥ 10%) losses were found at 1p21–31.1 (9 cases,
10%), 6cen-q24 (11 cases, 12%), 8p (10 cases, 11%), 9p21-ter (13
cases, 14%), 11q21–23.1 (10 cases, 11%), 13q13–21.1 (11 cases,
12%), and 17p (14 cases, 15%). The gains were clustered at 3q21-ter
(21 cases, 23%), 6p (10 cases, 11%), 7p (11 cases, 12%), 8q23-ter
(12 cases, 13%), 12cen-q15 (16 cases, 17%), 17q24-ter (12 cases,
13%), and 18q13.3–21 (19 cases, 20%). 
Verification of CGH results by direct measurements of
specific gene copy numbers 
The copy numbers of the c-MYC, RB1, and TP53 genes were
determined by interphase fluorescent in situ hybridization (FISH,
Galteland et al, 1999; data for 44 cases were taken from the refer-
ence). These copy numbers are given in Table 1 and show that
CGH detected gains at 8q24 in all cases where the FISH-detected
c-MYC copy number was increased relative to the DNA index.
Three plus 4 and 4 copies of c-MYC were found in cases 309/89
and 428/91, respectively, but no 8q gain was detected by CGH,
which is in agreement with the high DNA index of these tumours.
The gain of 8q24-ter by CGH observed in cases 399/88, with only
2 copies of the c-MYC gene, could be due to amplification of the
telomeric region distal of c-MYC. There was also good agreement
between the CGH results on 17p and the number of TP53 copies
(Table 1; see also Stokke et al, 2000). The exceptions were case
300/92 with loss of 17p by CGH but 2 TP53 copies, and case 8/92
with normal 17p by CGH and only 1 TP53 copy. Four of 12 cases
with loss of RB1 did not show any loss at 13q by CGH. Equally
interesting, case 458/88 showed high-level gain (i.e. ratio above
1.5) of chromosome 13 by CGH, while no RB1 copies could be
detected by FISH. Case 458/88 was the only one in this panel of
tumours which did not express pRB by immunoblotting and
immunohistochemistry (unpublished results). The three other
cases with 1 RB1 copy, but no losses on 13q by CGH, were small
lymphocytic lymphomas. Cases 123/84, 8/92, and 50/93 had 2
RB1 copies, in agreement with the CGH results that showed a
deletion telomeric of RB1. 
Frequency distribution of CGH aberrations 
The frequency distribution of the number of aberrations was
bimodal, with a natural cut-off between the groups at approximately
four aberrations (Figure 3). Attempts to fit this distribution to a single
Poisson distribution failed (P < 0.001). A linear combination of two
Poisson distributions with average values of 1.5 and 7.5, respectively,
gave significant fit (R2 = 0.94, P = 0.75). This shows that two groups
of lymphomas can be defined, one with a low number of aberrations
(0–3), and one with a high number of aberrations (≥ 4). 
Associations between CGH aberrations 
Table 2 shows that several of the aberrations tended to occur
together. Loss of 8p was correlated with seven other aberrations;
partially reflecting that 9 of 10 tumours with 8p loss had a high
number of aberrations. The deletions on 1p21–31.1, 8p, 9p21-ter,
and 13q13–21.1, frequently found in mantle cell lymphomas (see
below), showed pairwise associations. The loss of 8p, and the gains
of 3q21-ter, 7p, and 8q23-ter were also pairwise correlated. Three
chromosomes (6, 8, and 17) had frequent loss of one arm and gain of
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the other (Figure 1). For these chromosomes, the loss of one arm
was associated with gain of the other (Table 2). Gain of 12cen-q15
was negatively correlated with the majority of the other aberrations,
but none of these negative associations were statistically significant. 
Gain of 12cen-q15 and 18q13.3–21 were the only aberrations
which were found in more than 10% of the cases with a low
number (0–3) of aberrations. The frequencies of these aberrations
were less than two-fold higher among the cases with a high
number of aberrations (P = 0.25 and 0.11, respectively). The
11q21–23.1 deletion was found 2.7 times more frequently in the
lymphomas with many aberrations compared to the ones with few,
but the difference was not significant (P = 0.16). However, while
the loss of 11q21–23.1 occurred together with several other aberra-
tions in 4 MCL cases, three of the 4 losses at 11q21–23.1 in SLL
were found in tumours with a low number of aberrations. For the
remaining CGH aberrations, the frequency in the tumours with
many aberrations was >3.2 times higher than in the cases with few
aberrations (P < 0.05 in all cases). 
Lymphoma subtype and CGH aberrations 
A high number of CGH aberrations was associated with MCL and
DLBCL (P < 0.001). Figure 4 shows the distribution of the aberra-
tions according to lymphoma sub-types. Loss of 1p21–31.1 (P <
0.001), 8p (P = 0.02), 9p21-ter (P < 0.001), 11q21–23.1 (P = 0.03),
and 13q13–21.1 (P < 0.001) occurred more frequently in MCL
than in the other subtypes. Gain of 6p (P = 0.04) was associated
with DLBCL, and gain of 12cen-q15 was found more frequently in
SLL than in the other lymphoma groups (P = 0.04). 
The impact of CGH aberrations on cellular phenotypes 
The tumour-specific S phase and apoptotic fractions of the
tumours studied here have been published earlier (Stokke et al,
1998a). A high number of CGH aberrations (P < 0.001; Mann-
Whitney), as well as loss of 8p (P = 0.03) and 17p (P = 0.005), and
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Figure 3 Histogram of the total number of CGH aberrations in each
tumour. The number of tumours was plotted as a function of the number of
aberrations, i.e. the sum of the number of losses and gains. The distribution
could be fitted to a sum of two Poisson-distributions with average values of
1.5 and 7.5 (R2 = 0.94, P = 0.75), but no significant fit was obtained with a
single Poisson-distribution (P < 0.001; χ 2 test). 
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Figure 2 Averaged ratios and standard deviations for chromosomes 1, 3, 9, and 18 for 7 NHL cases. Case number is indicated to the left. The horizontal
dotted lines at 0.85 and 1.15 represent the cut-offs established from normal hybridizations for definition of losses (indicated by thin lines below the chromosome
fractional length axis) and gains (indicated by bold lines), respectively. Genomic imbalances and prognosis in non-Hodgkin’s lymphoma 1907
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gain of 3q21-ter (P < 0.001), 6p (P = 0.02), 7p (P = 0.007), and
8q23-ter (0.01) were associated with a high S phase fraction. None
of the CGH aberrations were associated with apoptotic fraction
(P ≥ 0.13). 
CGH aberrations and patient survival 
The prognostic values of the different gains and losses are given in
Table 3. The relative risks associated with a high number of CGH
aberrations, loss of 6cen-q24, 8p, 9p21-ter, 11q21–23.1, 13q13–21.1
and 17p, and gain of 3q21-ter and 6p, were significantly higher than
one. Multivariate survival analysis revealed that the only indepen-
dent prognostic factors were loss of 11q21–23.1 and 17p, and gain
of 6p (Table 3). 
The CGH parameters with independent prognostic value were
analysed by Cox multivariate regression analysis together with
lymphoma sub-type, as well as clinical and other biological para-
meters (Table 4). All parameters except for treatment had signifi-
cant prognostic value in univariate analysis (Table 4), but only
–11q21–23.1,  –17p, +6p, and IPI had independent prognostic
value. S phase fraction had marginal significance in multivariate
analysis; further investigations have shown that the patients with
the CGH aberrations with independent prognostic value survive a
shorter time if the tumour S phase fraction is higher than 3% (data
not shown). The survival was similar for the patients receiving
different treatments (chemotherapy without doxorubicin,
chemotherapy with doxorubicin, ‘other’ treatments; P > 0.75 for
pairwise comparisons), and it will be demonstrated later (Figure 5)
that the prognostic value of the CGH parameters and IPI is high in
all these three treatment groups. 
In an attempt to construct a combined parameter, we noticed
that the –11q21–23.1,  –17p, and +6p CGH parameters were
negatively correlated (Table 2), which was not unexpected in
view of their independent prognostic value (Tables 3, 4). The
most logical way of combining these parameters would therefore
be to include cases in the ‘poor survival’ group if they had any
of these aberrations (and/or). This CGH combination parameter
(Figure 5A) was substituted in an analysis similar to the one
shown in Table 4 instead of the 3 individual CGH aberrations,
and was the only parameter together with IPI which came out
with significant prognostic value (data not shown). In a similar
fashion as above, a single binary combined ‘CGH/IPI’ parameter
was constructed such that cases were allocated to the ‘poor
survival’ group if they had any of the three prognostic CGH
aberrations and/or a high IPI score (i.e. IPI > 2). The prognostic
value of the combined CGH/IPI parameter is shown in Figure
5C. When this parameter was entered into the multivariate
analysis as shown in Table 4 instead of the CGH aberrations
and IPI, it emerged as the only significant parameter, while S
phase again had marginal significance (data not shown). This
‘backtesting’ of the combined parameter in multivariate analysis
strongly suggests that we have chosen the best way (with this
simple approach) of combining the individual parameters with
independent prognostic value. 
The survival according to the combined CGH/IPI parameter
is shown for patients receiving different treatments (Figures 5D,
E, F), with different lymphoma subtypes (Figures 6A, B, C, D),
for the patients assessed at the first presentation (Figure 6E),
as well as for the patients with relapsed NHL (Figure 6F).
CGH/IPI had high prognostic value in all these sub-groups
(P ≤ 0.006). 
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DISCUSSION 
Chromosomal aberrations have high prognostic value and are used
for treatment stratification in acute lymphoblastic leukemia (Pui
and Evans, 1998). Intensive combination chemotherapy can cure
almost half of the patients with aggressive NHL (e.g., Fisher et al,
1993). It is therefore important to establish reliable prognostic
factors for treatment stratification of NHL patients with large
differences with respect to survival. Traditionally, histology and
stage have been used as the criteria for selection of NHL patients
for different types of therapy. Clinical parameters (IPI, The
International Non-Hodgkin’s Lymphoma Prognostic Factors
Project, 1993), and tumour cell proliferation (Stokke et al, 1998b
and references therein) are known prognostic factors in B-cell
NHL, which, however, have not yet been much used for treatment
stratification. In this retrospective study, we have identified three
chromosomal aberrations with high and independent prognostic
value in B-cell NHL. Loss of 11q21–23.1 and 17p, and gain of 6p
Table 3 Prognostic values of CGH aberrations in B-cell NHLa
Aberration (No. of cases  Univariate analysis Multivariate analysisd
with aberration) Relative riskb 95% Confidence P-valuec Relative riskb 95% Confidence P-value 
interval interval
–1p21–31.1 (9) 1.7 0.78–3.9 0.18 0.80 
–6cen-q24 (11) 2.1 1.1–4.2 0.04 0.64 
–8p (10) 3.3 1.6–6.8 0.002 0.27 
–9p21-ter (13) 2.1 1.1–4.0 0.02 0.67 
–11q21–23.1 (10) 3.8 1.9–7.8 < 0.001 6.8 3.1–15 < 0.001 
–13q13-21.1 (11) 2.3 1.2–4.5 0.01 0.57 
–17p (14) 4.4 2.2–8.6 < 0.001 7.2 3.5–15 < 0.001 
+3q21-ter (21) 1.9 1.0–3.5 0.04 0.52 
+6p (10) 4.2 2.0–8.8 < 0.001 8.8 3.9–20 < 0.001 
+7p (11) 1.3 0.60–3.0 0.47 
+8q23-ter (12) 1.9 0.95–3.8 0.07 0.92 
+12cen–q15 (15) 0.99 0.42–2.3 0.98 
+17q24-ter (12) 1.3 0.58–2.9 0.54 
+18q13.3–21 (19) 1.0 0.54–2.0 0.94 
#CGH aberrations > 3 (33) 3.7 2.1–6.6 < 0.001 0.38 
aSurvival data were available for 92 patients. bRelative to the cases without the respective aberration. Cox regression analysis was employed. Significant values
are in bold print. cFrom Cox regression analysis. The log-rank test gave p-values with less than 15% deviation from the values in the table. dAberrations with
P<0.20 in univariate analysis were included in Cox forward and backward multivariate regression analysis (identical results). 
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were all associated with relative risks larger than 5. The
International Prognostic Index was the only other parameter with
significant independent prognostic value, and a simple binary
combination parameter of the three CGH aberrations and IPI had
high prognostic value for groups of patients with various
lymphoma sub-types, having received different treatments, and
presenting with primary or relapse disease. 
In agreement with earlier studies, we found a number of recur-
rent losses and gains common to several sub-types of B-cell NHL.
CGH is a relatively new technique, and the sensitivity and speci-
ficity of the method in terms of absolute copy numbers of specific
loci have only been documented in a few reports (Kallionemi et al,
1994b; Bentz et al, 1995, 1996; Tirkkonen et al, 1998). For 64 of
the cases reported in this study, we have also performed interphase
FISH to directly assess the copy number of the c-MYC, RB1, and
TP53 gene loci. The results obtained with c-MYC and TP53 docu-
ment that, at least when employing the criteria described here,
CGH is sensitive enough to detect gain and loss of one copy,
respectively. However, this sensitivity depends on a predominance
of tumor cells in the sample (Kallioniemi et al, 1994a). Four of 12
cases with RB1 deletion by FISH did not show a reduced ratio at
13q14 by CGH. This may imply a poor sensitivity of CGH at this
locus, but it is more likely that the deleted regions around RB1 are
so small in many cases that CGH is not able to detect them. The
specificity of CGH appears to be high, since only one case without
FISH aberration was found to have CGH aberration at the corre-
sponding locus. 
Twelve of the frequent (>10% of cases) CGH aberrations
reported here have been observed in NHL before (Bentz et al,
1995, 1996, 2000; Monni et al, 1996, 1998; Dierlamm et al, 1997;
Autio et al, 1998; Beà et al, 1999). Seven of these 12 aberrations,
the losses at 6cen-q24, 11q21–23.1, and 13q13–21.1, and the gains
at 3q21-ter, 7p, 12cen-q15, and 18q13.3–21, are frequent findings
also in classical cytogenetic studies (Heim and Mitelman, 1995).
Moreover, banding techniques have revealed frequent rearrange-
ments involving the 5 other regions (1p, 6p, 9p, 8q, and 17p) in 
B-cell NHL (Heim and Mitelman, 1995). CGH studies in NHL
indicate that the rearrangements at the latter five chromosomal
regions are not balanced (this work; Bentz et al, 1995; 1996; 2000;
Monni et al, 1996, 1998; Dierlamm et al, 1997; Beà et al, 1999).
Some of the aberrations were local in the majority of cases where
they occurred. Our data defined 1p21–31.1 as a consensus region
for the losses at 1 p, in excellent agreement with the results of
others (Monni et al, 1996, 1998; Beà et al, 1999; Bentz et al,
2000). Interestingly, an almost identical consensus region for the
losses at 1 p was found in breast (Tirkkonen et al, 1998) and
colorectal carcinomas (DeAngelis et al, 1999). The losses at 11q
were also mostly local, with a consensus region at 11q21–23.1,
again in perfect agreement with the minimal common region of
deletion determined by others (Monni et al, 1998; Beà et al, 1999;
Bentz et al, 2000). 
Novel findings of this work include the frequent loss of 8p, and the
gain of 17q24-ter. The loss of 8p was associated with the gain of 8q
(Table 2). The 17q gains were associated with 17p losses, and may be
the result of formation of an isochromosome 17q in some cases. 
Suggested candidates for tumour suppressor genes and proto-
oncogenes at the chromosomal regions which are frequently lost
and gained, respectively, include the ATM gene at 11q23.1
(Bullrich et al, 1999; Schaffner et al, 2000), the TP53 gene at
17p13.1 (Stokke et al, 2000), and the BCL-2 gene at 18q21
(Monni et al, 1997). Other tumour suppressor genes and proto-
oncogenes, which are located within the frequently altered
regions, include p16INK4a (9p21), RB-1 (13q14), BCL6 (3q27),
CCND3 (6p), and c-MYC (8q24). We have investigated the
expression of p16, pRB, bc16, cyclin D3, and c-myc by
immunoblotting and immunohistochemistry in the tumours
presented in this paper (unpublished). Additionally, we have
determined the methylation status of the p16INK4a gene (E
Hovig and T Stokke, unpublished). We did not find any
decreased expression of p16 and pRB in the tumors with 9p21-
ter and 13q13–21.1 (RB1) deletions, respectively, compared to
the others. Case 458/88 was the only case that did not express
pRB; this case had high-level amplification of 13q by CGH, but
no RB-1 alleles (Galteland et al, 1999). Also, none of 13 cases
with 9p21-ter loss by CGH had detectable methylation of the
p16INK4 gene. The cases with gain of 3q21-ter, 6p, and 8q23-ter
did not show enhanced expression of bc16, cyclin D3, and c-
myc, respectively, compared to the others. Hence, the identities
Table 4 Prognostic values of CGH aberrations, biological and clinical parameters in B-cell NHLa
Aberration (No. of cases with Univariate analysis Multivariate analysisd
aberration or phenotype) Relative riskb 95% Confidence  P-valuec Relative riskb 95% Confidence P-value
interval interval
–11q21–23.1 (10) 3.8 1.9–7.8 <0.001 10 4.3–23 <0.001 
–17p (14) 4.4 2.2–8.6 <0.001 5.0 2.4–11 <0.001 
+6p (10) 4.2 2.0–8.8 <0.001 6.7 2.9–16 <0.001 
S phase fraction > 3% (30) 3.1 1.8–5.6 <0.001 0.05 
IPI > 2 (25) 3.9 2.1–7.1 <0.001 3.7 1.8–7.5 <0.001 
Lymphoma subtype FCL (36)e 0.41 0.22–0.75 0.004 0.07 
Relapse (vs. primary) biopsy (30) 2.3 1.4–4.1 0.002 0.20 
cyclin D1 expression (14) 2.4 1.2–4.6 0.01 0.17 
t(14;18) (37) 0.53 0.29–0.94 0.03 0.35 
B symptoms (22) 2.7 1.5–4.9 0.001 0.19 
Treatmentf >0.75
aSurvival data were available for 92 patients. bRelative to the cases without the respective aberration or phenotype. Cox regression analysis was employed.
Significant values are in bold print. cFrom Cox regression analysis. The log-rank test gave P-values with less than 15% deviation from the values in the table.
dAberrations with P < 0.20 in univariate analysis were included in Cox forward and backward multivariate regression analysis (identical results). eFCL patients
(median survival: 83 months) survived longer than the other patients (median survival: 33 months). There were no significant differences between the survival in
the other lymphoma subtypes (P > 0.12). fPatient treatments were essentially chemotherapy with (39 cases), or without (35 cases) doxorubicin, or other types of
treatment (18 cases; interferon, radiation). The survival was not different in these 3 groups (P > 0.75 for all 3 pairwise comparisons; log-rank test). 1910 T Stokke et al
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Figure 5 Survival in NHL according to CGH parameters and IPI status: combination of the parameters and prognostic value for patients receiving different
treatments. Kaplan-Meyer plots were generated for all 92 patients for cases with the presence (solid lines), or absence (dotted lines) of –11q21–23.1 and/or
–17p and/or +6p (A; relative risk (RR) = 13), IPI > 2 (B; RR = 3.9), and –11q21–23.1 and/or –17p and/or +6p and/or IPI>2 (combined CGH/IPI parameter, C;
RR = 26). Survival was also assessed for patients receiving chemotherapy without doxorubicin (D, 35 cases), with doxorubicin (E, 39 cases), or other therapy
(F, 18 cases) according to the presence (solid lines), or absence (dotted lines) of –11q21–23.1 and/or –17p and/or +6p and/or IPI > 2 (combined CGH/IPI
parameter). P-values were less than 0.001 for all comparisons.Genomic imbalances and prognosis in non-Hodgkin’s lymphoma 1911
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Figure 6 Survival in NHL according to the combined CGH/IPI parameter: prognostic value for different histologies and primary/recurrent disease. Survival was
assessed for patients with small lymphocytic lymphoma (A, 17 cases), follicle centre lymphoma (B, 36 cases), mantle cell lymphoma (C, 13 cases), and diffuse
large B-cell lymphoma (D, 17 cases), as well as for the primary biopsy (E, 62 cases) and rebiopsy (F, 30 cases) patients according to the presence (solid lines),
or absence (dotted lines) of –11q21–23.1 and/or –17p and/or +6p and/or IPI>2 (combined CGH/IPI parameter). P-values were less than 0.001 for all
comparisons, except for MCL (P = 0.006). of the tumour suppressor genes and proto-oncogenes at these loci
need yet to be determined. 
Another novel finding in our study is that the number of aberra-
tions per tumour showed a bimodal distribution. The tumours with
a high number of aberrations (≥ 4) had a high S phase fraction.
Also, the patients with tumours with a high number of aberrations
had a much shorter survival time than the others, in agreement
with the results of classical cytogenetic studies (reviewed by
Knutsen, 1998). As expected, most of the aberrations were found
more frequently in the tumours with many aberrations. However,
several of these presumably secondary aberrations were associated
(Table 2), indicating specific oncogene and/or tumor suppressor
gene cooperation. 
Candidates for primary CGH aberrations in B-cell lymphomas,
i.e. aberrations found at a high frequency also in cases with few
aberrations, include the gains at 12cen-q15 and 18q13.3–21, and
possibly also the 11q21–23.1 deletions in small lymphocytic
lymphomas. Among these aberrations, loss of 11q and gain of
chromosome 12 have been defined as primary events from clas-
sical cytogenetic studies (Mitelman et al, 1994). Interestingly, the
gains at 12cen-q15 and 18q13.3–21 did not have any prognostic
value, suggesting that additional, ‘secondary’ events are required
for evolution towards a more aggressive malignant lymphoma. 
None of the aberrations detected by CGH were specific (i.e.
diagnostic) for any lymphoma sub-type. However, several of the
aberrations were found at a significantly higher frequency in some
lymphoma sub-types, such as +12cen-q15 in SLL, –1p21–31.1,
–8p, –9p21-ter, –11q21–23.1, –13q13–21.1 in MCL, and +6p in
DLBCL. Gain of chromosome 12 or parts of this chromosome has
been observed by others in SLL (Bentz et al, 1995; Autio et al,
1998). However, 12cen–q15 gain was more frequent in SLL in this
study (37%). The mantle cell lymphomas typically had a high
number of aberrations, and the losses at 1p21–31.1, 8p, 9p21-ter,
11q21–23.1, and 13q13–21.1 were more frequent in this subset of
NHL, in concordance with the results of others (Monni et al, 1998;
Beà et al, 1999; Bentz et al, 2000). Interestingly, the losses at
1p21–31.1, 8p, 9p21-ter, and 13q13–21.1 typically occurred
together (Table 2), and together with cyclin D1 over-expression
caused by a t(11;14) translocation (unpublished results). Gain of
3q21-ter was found in almost 50% of the MCL cases, but this aber-
ration is common in all types of NHL, including MZL (Monni
et al, 1996; Dierlamm et al, 1997; Monni et al, 1998; Beà et al,
1999; Bentz et al, 2000; Figure 4). Concerning the diffuse large B-
cell lymphomas, we found gain of 6p at a similar frequency (24%)
as Monni et al (1996; 21%), but a higher incidence of 17p losses
(29%) than Monni et al (1996; 3%). 
Since patients with B-cell lymphomas with a high S phase frac-
tion have a poor prognosis (Stokke et al, 1998b), it is of particular
interest to identify the genetic aberrations responsible for this
phenotype. The losses of 8p and 17p, and the gains of 3q21-ter,
6p, 7p and 8q23-ter were associated with a high S phase fraction
(Table 4). Four of these aberrations are associated pairwise (–8p,
+3q21-ter, +7p, +8q23-ter). Hence, not all four of these aberra-
tions necessarily target genes that are important in the control of
cell proliferation. The anti-proliferative activities of wild-type
p53 are well documented in the literature (for reviews, see: Sherr,
1996; Levine, 1997), and our previous study showed that a high S
phase fraction was characteristic for NHL cases with either muta-
tions in TP53, loss of TP53, or clonal expression of p53 (Stokke
et al, 2000). 
Several aberrations with prognostic information were found in
this study (Table 3). Multivariate analysis showed that loss of
11q21-23.1 (ATM) and 17p (TP53), and gain of 6p by CGH were
independent prognostic factors. Other studies have shown that loss
of 17p or any aberration in the TP53 pathway are strong prog-
nostic factors in all subtypes of NHL (Sander et al, 1993; Tilly et
al, 1994; Dohner et al, 1995; Schoch et al, 1995; Hernandez et al,
1996; Panayiotidis and Kotsi, 1999; Dohner et al, 2000; Stokke
et al, 2000; reviewed by Knutsen, 1998), while 11q deletions are
unfavorable for patients with SLL/CLL (Dohner et al, 1997;
Panayiotidis and Kotsi, 1999; Dohner et al, 2000). Schouten et al
(1990) described gain of chromosome 6 as an adverse prognostic
sign in a group of patients with all types of NHL. 
Interestingly, S phase fraction, presence of BCL1 and BCL2
translocations, lymphoma subtype, biopsy status (primary vs
secondary), as well as B symptoms, became non-significant to
predict prognosis when entered into Cox multivariate analysis
together with the 3 CGH aberrations and IPI (Table 4). An ‘and/or’
combinatory scheme was found to incorporate the prognostic
CGH aberrations and IPI into a single binary parameter which had
high prognostic value for patients receiving different treatments,
with various lymphoma subtypes, and primary as well as relapse
cases (Figures 5, 6). The prognostic chromosomal imbalances
identified here clearly warrant large prospective studies (e.g. by
FISH) to evaluate whether prognostication and treatment stratifi-
cation of NHL can be based on chromosomal aberrations. 
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